HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $30
HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $30
HC Wainwright & Co.維持對EyePoint製藥的買入，將目標股價下調至30美元
HC Wainwright & Co. analyst Yi Chen maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and lowers the price target from $33 to $30.
HC Wainwright & Co. 分析師陳毅維持EyePoint Pharmicals（納斯達克股票代碼：EYPT）的買入並將目標股價從33美元下調至30美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。